NCT07483242Completed
Individualized Surgical Guidance in HCC-BDTT
Individualized Surgical Guidance for Hepatocellular Carcinoma With Bile Duct Tumor Thrombus: A Causal Modeling Study Integrating Preoperative Imaging and Clinical Features
Source: ClinicalTrials.gov · Last updated 19 Mar 2026
Brief summary (registry, in English)
The Rboost causal model can identify patients who are most likely to benefit among HCC-BDTT patients. Adherence to the individualized recommendation improves survival. This data-driven tool offers vital support for precision surgical decision-making in this high-risk disease.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 151 (actual)
- First submitted
- 8 Mar 2026
- Start date
- 1 Aug 2024
- Primary completion date
- 1 Jun 2025
- Lead sponsor
- First Affiliated Hospital, Sun Yat-Sen University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07483242
What you commit to
- Study type: Observational
- Participants enrolled: 151
- From 1 Aug 2024 to the primary completion date, 1 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pathological findings indicating concurrent cholangiocarcinoma and HCC;
Other illness
- Significant comorbidities (e.g., severe cardiac or renal failure) that could affect surgical outcomes.
Other
- Loss to follow-up, preventing outcome evaluation, or insufficient clinical data for analysis.
Who the study is looking for
- Pathologically confirmed HCC with BDTT;
- Absence of extrahepatic malignancies at the time of HCC diagnosis;
- Undergone R0 curative hepatectomy;
- No prior antitumor therapies, such as chemotherapy or immunotherapy, before surgery;
- Availability of preoperative imaging (CT or MRI) with standardized tumor evaluation.
Age in the registry: 31 years to 80 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| China, Guangdong Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.